Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women?

Caroline C. Marrs, Maged M. Costantine

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

Preeclampsia is a multisystem disorder that affects 3% to 5% of pregnant women and remains a significant source of short-term and long-term maternal and neonatal mortality and morbidity. Many professional societies recommend the use of low-dose aspirin to prevent preeclampsia in high-risk women. Owing to the similarities in pathophysiology between preeclampsia and atherosclerotic cardiovascular disease, and the encouraging data from preclinical and pilot clinical studies, pravastatin has been proposed for preventing preeclampsia. However, before statin administration becomes part of routine clinical practice, a large, well-designed, and adequately powered randomized-controlled trial is needed.

Original languageEnglish (US)
Pages (from-to)161-168
Number of pages8
JournalClinical Obstetrics and Gynecology
Volume60
Issue number1
DOIs
StatePublished - 2017
Externally publishedYes

Keywords

  • aspirin
  • pravastatin
  • preeclampsia
  • pregnancy
  • statins

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women?'. Together they form a unique fingerprint.

Cite this